ENFLAMATUAR BAĞIRSAK HASTALIĞI VE TIBBİ BİTKİLER: GÜNCEL BİR GÖZDEN GEÇİRME

Abstract

Amaç: Enflamatuar bağırsak hastalığı (EBH), ülserasyon, kanama, sıvı ve elektrolit kaybı ile karakterize, atak ve remisyon dönemlerinden oluşan gastrointestinal sistemin (GİS) kronik enflamasyonudur. Ülseratif kolit ve Chron, etiyolojisi ve patogenezi tam olarak belli olmayan EBH’nin majör klinik formlarıdır. Son yıllarda ülkemizde ve dünyada insidansı ve prevalansı gittikçe artan EBH, bireylerin yaşam kalitesini olumsuz etkilemektedir. Bu durum hastalığın tedavisini daha da önemli hale getirmektedir. Fakat bu tedavi yöntemleri hastalığın remisyon süresinin uzatılması ve progresyonunun önlenmesi için yetersiz kalabilmektedir. Bu nedenle hastalar esas tedavilerine ek olarak farklı tamamlayıcı tedavi arayışlarına yönelmektedir. Bu yöntemler arasında hastaların en sık başvurduğu tamamlayıcı tedavi, bitkisel ürünlerdir. Sonuç ve Tartışma: Bitkisel ürünlerin kullanımı, hastalık üzerinde olumlu etkiler yapabildiği gibi olumsuz etkilere de yol açabilmektedir. Bu nedenle belli standartlara sahip ürünlerin uygun hastalıkta, uygun formda, uygun dozda ve hekim/eczacı kontrolünde kullanılması gerekmektedir. Literatürdeki çalışmalar değerlendirildiğinde; enflamatuar bağırsak hastalıklarında kullanılan tıbbi bitkilerin fazlalığına rağmen birçoğunun potansiyel etki mekanizmasının ve olumlu/olumsuz etkilerinin tam olarak ortaya konmadığı görülmektedir. Bu bitkilerin yanlış ve bilinçsizce kullanımı hastalığın seyrinin kötüleşmesine yol açabileceğinden enflamatuar bağırsak hastalıklarında kullanılan tıbbi bitkilerle ilgili daha fazla araştırmaya ihtiyaç duyulmaktadır.

Keywords

• Chron hastalığı
• enflamatuar bağırsak hastalığı
• tıbbi bitkiler
• ülseratif kolit

ENFLAMMATORY BOWEL DISEASES AND MEDICINAL PLANTS: A CURRENT REVIEW

Abstract

Objective: Enflammatory bowel disease (EBD) is a chronic enflammation of the gastrointestinal tract (GIS) that consists of episodes of attacks and remissions characterized by ulceration, bleeding, fluid and electrolyte loss. Ulcerative colitis and Chron, are the major clinical forms of EBD, the etiology and pathogenesis of which are unclear. EBD, the incidence and prevalence of which has been increasing in our country and in the world in recent years, negatively affects the quality of life of people. This makes the treatment of the disease even more important. However, these treatment methods may be insufficient for prolonging the remission period of the disease and preventing its progression. For this reason, patients tend to seek different complementary therapies in addition to their medical treatments. Among these methods, the most frequently applied complementary therapy is herbal products. Result and Discussion: The use of herbal products can have positive effects on the disease as well as cause negative effects. For this reason, products with certain standards should be used in the appropriate disease, in the appropriate form, in the appropriate dose and under the control of the doctor / pharmacist. When the studies in the literature are evaluated; Despite the abundance of medicinal herbs used in anxiety and sleep disordersenflammatory bowel disease, the potential mechanism of action and positive/negative effects of many of them have not been fully revealed. Since the wrong and unconscious irrational use of these herbs may lead to worsening of the course of the disease, more researches are needed to examine examine medicinal herbs used in enflammatory bowel disease.

Keywords

• Chrons disease
• enflammatory bowel disease
• medicinal herbs
• ulcerative colitis

References

1. 1. Cohen, N.A., Rubin, D.T. (2021). New targets in inflammatory bowel disease therapy: 2021. Current Opinion in Gastroenterology, 37(4), 357-363. [CrossRef]
2. 2. Genaro, L.M., Gomes, L.E.M., Franceschini, A.P.M.F., Ceccato, H.D., de Jesus, R.N., Lima, A.P., Nagasako, C.K., Fagundes, J.J., Ayrizono, M.L.S., Leal, R.F. (2021). Anti-TNF therapy and immunogenicity in inflammatory bowel diseases: A translational approach. American Journal of Translational Research, 13(12), 13916-13930.
3. 3. Guzzo, G.L., Andrews, J.M., Weyrich, L.S. (2022). The neglected gut microbiome: Fungi, protozoa, and bacteriophages in inflammatory bowel disease. Inflammatory Bowel Disease, 28(7), 1112-1122. [CrossRef]
4. 4. Kuenzig, M.E., Manuel, D.G., Donelle, J., Benchimol, E.I. (2020). Life expectancy and health-adjusted life expectancy in people with inflammatory bowel disease. CMAJ: Canadian Medical Association Journal, 192(45), E1394-E1402. [CrossRef]
5. 5. Rogler, G., Singh, A., Kavanaugh, A., Rubin, D.T. (2021). Extraintestinal manifestations of inflammatory bowel disease: Current concepts, treatment, and implications for disease management. Gastroenterology, 161(4), 118-1132. [CrossRef]
6. 6. Rubin, D.T., Griffith, J., Zhang, Q., Hepp, Z., Keshishian, A. (2021). The impact of intestinal complications on health care costs among patients with inflammatory bowel disease treated with anti-tumor necrosis factor therapies. Inflammatory Bowel Diseaes, 27(8), 1201-1209. [CrossRef]
7. 7. Sara, J.C., Zielińska, M., Sokal, A., Filip, R. (2022). Genetic and epigenetic etiology of inflammatory bowel disease: An update. Genes, 13(12), 2388. [CrossRef]
8. 8. Szymczak-Tomczak, A., Ratajczak, A.E., Kaczmarek-Ryś, M., Hryhorowicz, S., Rychter, A.M., Zawada, A., Slomski, R., Dobrowolska, A., Krela-Kaźmierczak, I. (2022). Pleiotropic effects of vitamin D in patients with inflammatory bowel diseases. Journal of Clinical Medicine, 11(19), 5715. [CrossRef]

9. 9. Zhou, Y., Wang, D., Yan, W. (2023). Treatment effects of natural products on inflammatory bowel disease in vivo and their mechanisms: Based on animal experiments. Nutrients, 15(4), 1031. [CrossRef]
10. 10. Talhaoğlu, D. (2021). Geleneksel ve tamamlayıcı tedavi uygulamaları. Bütünleyici ve Anadolu Tıbbı Dergisi, 3(1), 16-29. [CrossRef]
11. 11. Öztürk, Y.E., Dömbekci, H.A., Ünal, S.N. (2020). Geleneksel tamamlayıcı ve alternatif tıp kullanımı. Journal of Integrative and Anatolian Medicine, 3(1), 23-35.
12. 12. Yeshi, K., Ruscher, R., Hunter, L., Daly, N.L., Loukas, A., Wangchuk, P. (2020). Revisiting inflammatory bowel disease: Pathology, treatments, challenges and emerging therapeutics including drug leads from natural products. Journal of Clinical Medicine, 9(5), 1273. [CrossRef]
13. 13. Adam, H., Alqassas, M., Saadah, O.I., Mosli, M. (2020). Extraintestinal manifestations of inflammatory bowel disease in middle Eastern patients. Journal of Epidemiology and Global Health, 10(4), 298-303. [CrossRef]
14. 14. Agrawal, M., Jess, T. (2022). Implications of the changing epidemiology of inflammatory bowel disease in a changing world. United European Gastroenterology Journal, 10(10), 1113-1120. [CrossRef]
15. 15. Nimmons, D., Limdi, J.K. (2016). Elderly patients and inflammatory bowel disease. World Journal of Gastrointestinal Pharmacology and Therapeutics, 7(1), 51-65. [CrossRef]
16. 16. Steven, R., Brant, M.D., Geoffrey, C., Nguyen, M.D. (2008). Is there a gender difference in the prevalence of Crohn's disease or ulcerative colitis? Inflammatory Bowel Diseases, 14(2), S2-S3. [CrossRef]
17. 17. Goodman, W.A., Erkkila, I.P., Pizarro, T.T. (2020). Sex matters: Impact on pathogenesis, presentation and treatment of inflammatory bowel disease. Nature Reviews Gastroenterology & Hepatology, 17(12), 740-754. [CrossRef]
18. 18. Matricon, J., Barnich, N., Ardid, D. (2010). Immunopathogenesis of inflammatory bowel disease. Self Nonself, 1(4), 299-309. [CrossRef]
19. 19. Niriella, M.A., De Silva, A.P., Dayaratne, A.H., Ariyasinghe, M.H., Navarathne, M.M., Peiris, R.S., Samarasekara, D.N., Satharasinghe, R.L., Rajindrajith, S., Dassanayake, A.S., Wickramasinghe, A.R., de Silva, H.J. (2020). Prevalence of inflammatory bowel disease in two districts of Sri Lanka: A hospital based survey. BMJ Gastroenterology, 19, 10-32. [CrossRef]
20. 20. Wilson, J., Hair, C., Knight, R., Catto-Smith, A., Bell, S., Kamm, M., Desmond, P., McNeil, J., Connell, W. (2010). High incidence of inflammatory bowel disease in Australia: A prospective population-based Australian incidence study. Inflammatory Bowel Disease, 16, 1550-1556. [CrossRef]
21. 21. Özgürsoy Uran, B.N., Sarıtaş Yüksel, E., Ünsal Avdal, E., Arkan, B. (2019). İnflamatuvar barsak hastalıklarında epidemiyolojik özellikler ve hastalık farkındağı; İzmir örneği ile kesitsel bir çalışma. Akademik Gastroenteroloji Dergisi, 18(3), 112-119. [CrossRef]
22. 22. Tözün, N., Atuğ, O., İmeryüz, N., Hamzaoğlu, H.O., Tiftikçi, A., Parlak, E., Dağlı, U., Ülker, A., Hülagü, S., Akpınar, H., Tuncer, C., Süleymanlar, I., Övünç, O., Hilmioğlu, F., Aslan, S., Türkdoğan, K., Bahçecioglu, H. I., Yurdaydın, C., Barghi, I., Şentürk, O., Şimşek, I., Doğan, I., Akça, S., Ebut, E., Aladağ, M., Kav, T., Tuncer, I. (2009). Members of The Turkish IBD Study Group. Clinical characteristics of inflammatory bowel disease in Turkey: A multicenter epidemiologic survey. Journal of Clinical Gastroenterology, 43, 51-7.
23. 23. Yaxi, Z., Wang, D., Yan, W. (2023). Treatment effects of natural products on inflammatory bowel disease in vivo and their mechanisms: Based on animal experiments. Nutrients, 15(4), 1031. [CrossRef]
24. 24. Agrawal, M., Allin, K.H., Petralia, F., Colombel, J.F., Jess, T. (2022). Multiomics to elucidate inflammatory bowel disease risk factors and pathways. Nature Reviews Gastroenterology & Hepatology, 19, 399-409. [CrossRef]
25. 25. Abegunde, A.T., Muhammad, B.H., Ali, T. (2016). Preventive health measures in inflammatory bowel disease. World Journal of Gastroenterology, 22(34), 7625-7644. [CrossRef]
26. 26. Kilby, K., Mathias, H., Boisvenue, L., Heisler, C., Jones, J.L. (2019). Micronutrient absorption and related outcomes in people with inflammatory bowel disease: A review. Nutrients, 11(6), 1388. [CrossRef]
27. 27. Yaxi Koloski, N.A., Bret, L., Radford-Smith, G. (2008). Hygiene hypothesis in inflammatory bowel disease: A critical review of the literature. World Journal of Gastroenterology, 14(2), 165-173. [CrossRef]
28. 28. Barnes, A., Spizzo, P., Bampton, P., Andrews, J.M., Fraser, R.J., Mukherjee, S., Mountifield, R. (2023). Examining the influence of inflammatory bowel disease medications on sleep quality. JGH: Journal of Gastroenterology and Hepatology Open, 7(3), 190-196. [CrossRef]
29. 29. Schirmer, M., Franzosa, E.A., Lloyd-Price, J., McIver, L.J., Schwager, R., Poon, T.W., Ananthakrishnan, A.N., Andrews, E., Barron, G., Lake, K., Prasad, M., Sauk, J., Stevens, B., Wilson, R.G., Braun, J., Denson, L.A., Kugathasan, S., McGovern, D.P.B., Vlamakis, H., Xavier, R.J., Huttenhower, C. (2018). Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. Nature Microbiology, 3(3), 337-346. [CrossRef]
30. 30. Silva, F.A., Rodrigues, B.L., Ayrizono, M.L., Leal, R.F. (2016). The immunological basis of inflammatory bowel disease. Gastroenterology Research and Practice, 2097274. [CrossRef]
31. 31. Zhang, H.M., Yuan, S., Meng, H., Hou, X.T., Li, J., Xue, J.C., Li, Y., Wang, Q., Nan, J.X., Jin, X.J., Zhang, Q.G. (2022). Stem cell-based therapies for inflammatory bowel. International Journal of Molecular Sciences, 23(15), 8494. [CrossRef]
32. 32. Estevinho, M.M., Leão Moreira, P., Silva, I., Laranjeira Correia, J., Santiago, M., Magro, F. (2022). A scoping review on early inflammatory bowel disease: Definitions, pathogenesis, and impact on clinical outcomes. Therapeutic Advances in Gastroenterology, 15. [CrossRef]
33. 33. Hagan, M., Hayee, B.H., Rodriguez-Mateos, A. (2021). (Poly)phenols in inflammatory bowel disease and irritable bowel syndrome: A review. Molecules, 26(7), 1843. [CrossRef]
34. 34. Moran, C.J., Klein, C., Muise, A.M., Snapper, S.B. (2015). Very early-onset inflammatory bowel disease: Gaining insight through focused discovery. Inflammatory Bowel Diseases, 21(5), 1166-1175. [CrossRef]
35. 35. Tontini, G.E., Vecchi, M., Pastorelli, L., Neurath, M.F., Neumann, H. (2015). Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives. World Journal of Gastroenterology, 21(1), 21-46. [CrossRef]
36. 36. Geleneksel Bitkisel Tıbbi Ürünler Ruhsatlandırma Yönetmeliği, 2023. Erişim adresi https://www.resmigazete.gov.tr/eskiler/2023/02/20230203-5.htm/. Erişim tarihi: 11.10.2023.
37. 37. Sangpreecha, N., Chanmuang, S., Park, K.H., Sangar, M., Sharma, D., Song, D., Park, Y.J., Sung, H.M., Promyo, K., Ham, K.S. (2023). Effects of fermented onion on gut health in dextran sodium sulfate (DSS)-induced inflammatory bowel disease (IBD) rats. Applied Sciences, 13(3), 1590. [CrossRef]
38. 38. Pérez-Rubio, K.G., Méndez-Del Villar, M., Cortez-Navarrete, M. (2022). The role of garlic in metabolic diseases: A review. Journal of Medicinal Food, 25(7), 683-694. [CrossRef]
39. 39. De Conno, B., Pesce, M., Chiurazzi, M., Andreozzi, M., Rurgo, S., Corpetti, C., Seguella, L., Del Re, A., Palenca, I., Esposito, G., Sarnelli, G. (2022). Nutraceuticals and diet supplements in Crohn's disease: A general overview of the most promising approaches in the clinic. Foods, 11(7), 1044. [CrossRef]
40. 40. Ng, S.C., Lam, Y.T., Tsoi, K.K.F., Chan, F.K.L., Sung, J.J.Y. and Wu, J.C.Y. (2013), Systematic review: The efficacy of herbal therapy in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 38, 854-863. [CrossRef]
41. 41. Holleran, G., Scaldaferri, F., Gasbarrini, A., Currò, D. (2020). Herbal medicinal products for inflammatory bowel disease: A focus on those assessed in double-blind randomised controlled trials. Phytotherapy Research, 34, 77-93. [CrossRef]
42. 42. Langhorst, J., Wulfert, H., Lauche, R., Klose, P., Cramer, H., Dobos, G.J., Korzenik, J. (2015). Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. Journal of Crohn's and Colitis, 9(1), 86-106. [CrossRef]
43. 43. Triantafyllidi, A., Xanthos, T., Papalois, A., Triantafillidis, J.K. (2015). Herbal and plant therapy in patients with inflammatory bowel disease. Annals of Gastroenterology, 28(2), 210-220.
44. 44. Sebepos-Rogers, G.M., Rampton, D.S. (2017). Herbs and inflammatory bowel disease. Gastroenterology Clinics of North America, 46(4), 809-824. [CrossRef]
45. 45. Debnath, T., Kim, D.H., Lim, B.O. (2013). Natural products as a source of anti-inflammatory agents associated with inflammatory bowel disease. Molecules, 18, 7253-7270. [CrossRef]
46. 46. Ganji-Arjenaki, M., Rafieian-Kopaei, M. (2019). Phytotherapies in inflammatory bowel disease. Journal of Research in Medical Sciences, 24, 42. [CrossRef]
47. 47. Şen, A. (2022). Complementary medicines used in ulcerative colitis and unintended interactions with cytochrome P450-dependent drug-metabolizing enzymes. Turkish Journal of Medical Sciences, 52(5), 1425-1447. [CrossRef]
48. 48. Zhou, Y., Wang, D., Yan, W. (2023). Treatment effects of natural products on inflammatory bowel disease in vivo and their mechanisms: Based on animal experiments. Nutrients, 15(4), 1031. [CrossRef]
49. 49. Ramezani, M., Amiri, M.S., Zibaee, E., Boghrati, Z., Ayati, Z., Sahebkar, A., Emami, S.A. (2020). A review on the phytochemistry, ethnobotanical uses and pharmacology of Borago species. Current Pharmaceutical Design, 26(1), 110-128. [CrossRef]
50. 50. Lee, S.H., Kim, H.R., Noh, E.M., Park, J.Y., Kwak, M.S., Jung, Y.J., Yang, H.J., Ryu, M.S., Seo, H.Y., Jang, H., Kim, S.Y., Park, M.H. (2023). Anti-inflammatory effect and signaling mechanism of Glycine max hydrolyzed with enzymes from Bacillus velezensis KMU01 in a dextran-sulfate-sodium-induced colitis mouse model. Nutrients, 15(13), 3029. [CrossRef]
51. 51. Leite, C.D.S., Bonafé, G.A., Carvalho Santos, J., Martinez, C.A.R., Ortega, M.M., Ribeiro, M.L. (2022). The anti-inflammatory properties of licorice (Glycyrrhiza glabra)-derived compounds in intestinal disorders. International Journal of Molecular Sciences, 23(8), 4121. [CrossRef]
52. 52. Recinella, L., Chiavaroli, A., Ronci, M., Menghini, L., Brunetti, L., Leone, S., Tirillini, B., Angelini, P., Covino, S., Venanzoni, R., Zengin, G., Di Simone, S., Ciferri, M.C., di Giacomo, V., Cataldi, A., Rapino, M., Valerio, V.D., Orlando, G., Ferrante, C. (2020). Multidirectional pharma-toxicological study on Harpagophytum procumbens DC. ex Meisn.: An IBD-focused investigation. Antioxidants (Basel), 9(2), 168. [CrossRef]
53. 53. Yan, T., Luo, Y., Xia, Y., Hamada, K., Wang, Q., Yan, N., Krausz, K.W., Ward, J.M., Hao, H., Wang, P., Gonzalez, F.J. (2021). St. John's Wort alleviates dextran sodium sulfate-induced colitis through pregnane X receptor-dependent NFκB antagonism. Federation of American Societies for Experimental Biology Journal, 35(11), e21968. [CrossRef]
54. 54. Morshedzadeh, N., Shahrokh, S., Chaleshi, V., Karimi, S., Mirmiran, P., Zali, M.R. (2021). The effects of flaxseed supplementation on gene expression and inflammation in ulcerative colitis patients: An open-labelled randomised controlled trial. International Journal of Clinical Practice, 75, e14035. [CrossRef]
55. 55. Jarmakiewicz-Czaja, S., Zielińska, M., Helma, K., Sokal, A., Filip, R. (2023). Effect of Nigella sativa on selected gastrointestinal diseases. Current Issues in Molecular Biology, 45(4), 3016-3034. [CrossRef]
56. 56. Jalalipour, M., Yegdaneh, A., Talebi, A., Minaiyan, M. (2022). Salvia officinalis leaf extracts protect against acute colitis in rats. Research in Pharmaceutical Sciences, 17(4), 350-359. [CrossRef]
57. 57. Ivanova, T., Todorova-Popova, V., Mazova, N., Stoyanova, A., Damyanova, S. (2019). Extracts from physalis leaves (Physalis peruviana L.) for prospective application in medicine and cosmetics. Ukrainian Food Journal, 8, 34-44. [CrossRef]
58. 58. de Oliveira E.C.S., Dalmau, L.M., de Almeida Costa, C.A.R., de Almeida Junior, L.D., Ballard, C.R., Maróstica Junior, M.R., Stahl, M.A., Grimaldi, R., Witaicenis, A., Di Stasi, L.C. (2023). Dietary intervention with avocado (Persea americana Mill.) ameliorates intestinal inflammation induced by TNBS in rats. Inflammopharmacology, 31(1), 485-498. [CrossRef]
59. 59. Moon, H.J., Cha, Y.S., Kim, K.A. (2023). Blackcurrant alleviates dextran sulfate sodium (DSS)-induced colitis in mice. Foods, 12(5), 1073. [CrossRef]
60. 60. Pasalar, M., Shirzad, M., Tavakoli, A., Ahmadian-Attari, M.M., Taghizadeh, L. (2019). A preliminary study on Rosa damascena Mill L. oil in ulcerative colitis patients. Advances in Integrative Medicine, 6. S36-S37. [CrossRef]
61. 61. Medicherla, K., Ketkar, A., Sahu, B.D., Sudhakar, G., Sistla, R. (2016). Rosmarinus officinalis L. extract ameliorates intestinal inflammation through MAPKs/NF-κB signaling in a murine model of acute experimental colitis. Food and Function Journal, 7(7), 3233-3243. [CrossRef]
62. 62. Wanes, D., Toutounji, M., Sebai, H., Rizk, S., Naim, H.Y. (2021). Rosa canina L. can restore endoplasmic reticulum alterations, protein trafficking and membrane integrity in a dextran sulfate sodium-induced inflammatory bowel disease phenotype. Nutrients, 13(2), 441. [CrossRef]
63. 63. Yeom, J.E., Kim, S.K., Park, S.Y. (2022). Regulation of the gut microbiota and inflammation by β-caryophyllene extracted from cloves in a dextran sulfate sodium-induced colitis mouse model. Molecules, 27(22), 7782. [CrossRef]
64. 64. Batiha, G.E., Magdy Beshbishy, A., Wasef, L., Elewa, Y.H.A., Abd El-Hack, M.E., Taha, A.E., Al-Sagheer, A.A., Devkota, H.P., Tufarelli, V. (2020). Uncaria tomentosa (Willd. ex Schult.) DC.: A review on chemical constituents and biological activities. Applied Sciences, 10(8), 2668. [CrossRef]
65. 65. Feng, Y., Dai, W., Ke, J., Cui, Y., Li, S., Ma, J., Guo, W., Chen, G., Li, N., Li, Y. (2022). Protective effect of valerian extract capsule (VEC) on ethanol- and indomethacin-induced gastric mucosa injury and ameliorative effect of VEC on gastrointestinal motility disorder. Pharmaceutical Biology, 60(1), 1095-1105. [CrossRef]
66. 66. Bortolotti, M., Mercatelli, D., Polito, L. (2019). Momordica charantia, a nutraceutical approach for inflammatory related diseases. Frontiers in Pharmacology, 8(10), 486. [CrossRef]
67. 67. Jia, S., Shen, M., Zhang, F., Xie, J. (2017). Recent advances in Momordica charantia: Functional components and biological activities. International Journal of Molecular Sciences, 18(12), 2555. [CrossRef]
68. 68. Wang, F., Yuan, M., Shao, C., Ji, N., Zhang, H., Li, C. (2023). Momordica charantia-derived extracellular vesicles provide antioxidant protection in ulcerative colitis. Molecules, 28(17), 6182. [CrossRef]
69. 69. Aydın, G., Kaya, E. (2020). A review: Momordica charantia L.’s biological active components and its potential use in traditional therapies. International Journal of Traditional and Complementary Medicine Research, 1(2), 79-95.
70. 70. Khalid, Z., Hassan, S., Mughal, S., Hassan, S., Hassan, H. (2021). A review on biological attributes of Momordica charantia. Advances in Bioscience and Bioengineering, 9, 8. [CrossRef]
71. 71. Rashwan, H.K., Mahgoub, S., Abuelezz, N.Z., Amin, H.K. (2023). Black Cumin seed (Nigella sativa) in inflammatory disorders: Therapeutic potential and promising molecular mechanisms. Drugs and Drug Candidates, 2(2), 516-537. [CrossRef]
72. 72. Salehi, B., Quispe, C., Imran, M., Ul-Haq, I., Živković, J., Abu-Reidah, I.M., Sen, S., Taheri, Y., Acharya, K., Azadi, H., Del Mar Contreras, M., Segura-Carretero, A., Mnayer, D., Sethi, G., Martorell, M., Abdull Razis, A.F., Sunusi, U., Kamal, R.M., Rasul Suleria, H.A., Sharifi-Rad, J. (2021). Nigella plants- traditional uses, bioactive phytoconstituents, preclinical and clinical studies. Frontiers in Pharmacology, 12, 625386. [CrossRef]
73. 73. Jarmakiewicz-Czaja, S., Zielińska, M., Helma, K., Sokal, A., Filip, R. (2023). Effect of Nigella sativa on selected gastrointestinal diseases. Current Issues in Molecular Biology, 45(4), 3016-3034. [CrossRef]
74. 74. Nikkhah-Bodaghi, M., Darabi, Z., Agah, S., Hekmatdoost, A. (2019). The effects of Nigella sativa on quality of life, disease activity index, and some of inflammatory and oxidative stress factors in patients with ulcerative colitis. Phytotherapy Research, 33, 1027-1032. [CrossRef]
75. 75. Shakeri, F., Gholamnezhad, Z., Mégarbane, B., Rezaee, R., Boskabady, M.H. (2016). Gastrointestinal effects of Nigella sativa and its main constituent, thymoquinone: A review. Avicenna Journal of Phytomedicine, 6(1), 9-20.
76. 76. Lashgari, N.A., Momeni Roudsari, N., Khayatan, D., Shayan, M., Momtaz, S., Roufogalis, B.D., Roufogalis, B.D., Abdolghaffari, A.H., Sahebkar, A. (2022). Ginger and its constituents: Role in treatment of inflammatory bowel disease. BioFactors, 48, 7–21. [CrossRef]
77. 77. Ranjbar, F., Mohammadyari, F., Omidvar, A., Nikzad, F., Nargesi, N., Varmazyar, M., Dehghankar, S., & Vosoughian, F., Olangian-Tehrani, S., Nanbakhsh, S., Mansourian, T., Deravi, N., Tutunchian, Z., Salahi, M., Poudineh, M., Ghayyem, H. (2022). Zingiber officinale (Ginger) as a treatment for inflammatory bowel disease: A review of current literature. Frontiers in Drug Discovery, 2. [CrossRef]
78. 78. Shayesteh, F., Haidari, F., Shayesteh, A.A., Mohammadi-Asl, J., Ahmadi-Angali, K. (2020). Ginger in patients with active ulcerative colitis: A study protocol for a randomized controlled trial. Trials, 21, 278. [CrossRef]
79. 79. Ballester, P., Cerdá, B., Arcusa, R., Marhuenda, J., Yamedjeu, K., Zafrilla, P. (2022). Effect of Ginger on inflammatory diseases. Molecules, 27(21), 7223. [CrossRef]
80. 80. Fuloria, S., Mehta, J., Chandel, A., Sekar, M., Rani, N.N.I.M., Begum, M.Y., Subramaniyan, V., Chidambaram, K., Thangavelu, L., Nordin, R., Wu, Y.S., Sathasivam, K.V., Lum, P.T., Meenakshi, D.U., Kumarasamy, V., Azad, A.K., Fuloria, N.K. (2022). A comprehensive review on the therapeutic potential of Curcuma longa Linn. in relation to its major active constituent Curcumin. Frontiers in Pharmacology, 13, 820806. [CrossRef]
81. 81. Lima, A.M., Nascimento, C.E.C., Santos, C.H.M.D., Dourado, D.M., Siqueira, G.E.C., Rigo, G.M., Bernardi, L.U., Leonel, P.O.S., Matias, R., Ferreira, V.C., Souza, V.C.R.P. (2019). Effıcacy of Curcuma longa in the treatment of diversion colitis in rats. Arquivos Brasileiros de Cirurgia Digestiva, 32(3), e1456. [CrossRef]
82. 82. Yuandani Jantan, I., Rohani, A.S., Sumantri, I.B. (2021). Immunomodulatory effects and mechanisms of curcuma species and their bioactive compounds: A review. Frontiers in Pharmacology, 12, 643119. [CrossRef]
83. 83. Hagenlocher, Y., Satzinger, S., Civelek, M., Feilhauer, K., Köninger, J., Bischoff, S.C., Lorentz, A. (2017). Cinnamon reduces inflammatory response in intestinal fibroblasts in vitro and in colitis in vivo leading to decreased fibrosis. Molecular Nutrition & Food Research, 61(9). [CrossRef]
84. 84. Lonati, E., Sala, G., Corbetta, P., Pagliari, S., Cazzaniga, E., Botto, L., Rovellini, P., Bruni, I., Palestini, P., Bulbarelli, A. (2023). Digested Cinnamon (Cinnamomum verum J. Presl) bark extract modulates claudin-2 gene expression and protein levels under TNFα/IL-1β inflammatory stimulus. International Journal of Molecular Sciences, 24(11), 9201. [CrossRef]
85. 85. Hagenlocher, Y., Hösel, A., Bischoff, S.C., Lorentz, A. (2016). Cinnamon extract reduces symptoms, inflammatory mediators and mast cell markers in murine IL-10(-/-) colitis. The Journal of Nutritonal Biochemistry, 30, 85-92. [CrossRef]
86. 86. Catanzaro, D., Rancan, S., Orso, G., Dall'Acqua, S., Brun, P., Giron, M.C., Carrara, M., Castagliuolo, I., Ragazzi, E., Caparrotta, L., Montopoli, M. (2015). Boswellia serrata preserves intestinal epithelial barrier from oxidative and inflammatory damage. PLoS One, 10(5), e0125375.
87. 87. Elnawasany, S. (2023). Boswellia carries hope for patients with inflammatory bowel disease (IBD). Medicinal plants-chemical, biochemical, and pharmacological approache. IntechOpen, 2023. [CrossRef]
88. 88. Holtmeier, W., Zeuzem, S., Preiβ, J., Kruis, W., Böhm, S., Maaser, C., Raedler, A., Schmidt, C., Schnitker, J., Schwarz, J., Zeitz, M., Caspary, W. (2011). Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: Good safety profile but lack of efficacy, Inflammatory Bowel Diseases, 17(2), 573-582. [CrossRef]
89. 89. Nowak, W., Jeziorek, M. (2023). The role of Flaxseed in improving human health. Healthcare, 11(3), 395.
90. 90. Morshedzadeh, N., Shahrokh, S., Aghdaei, H.A., Amin Pourhoseingholi, M., Chaleshi, V., Hekmatdoost, A., Karimi, S., Zali, M.R., Mirmiran, P. (2019). Effects of flaxseed and flaxseed oil supplement on serum levels of inflammatory markers, metabolic parameters and severity of disease in patients with ulcerative colitis. Complementary Therapies in Medicine, 46, 36-43. [CrossRef]
91. 91. Palla, A.H., Gilani, A.U., Bashir, S., Ur Rehman, N. (2020). Multiple mechanisms of Flaxseed: Effectiveness in inflammatory bowel disease. Evidence Based Complement Alternative Medicine, 2020, 7974835. [CrossRef]
92. 92. Zhou, Q., Ma, L., Zhao, W., Zhao, W., Han, X., Niu, J., Li, R., Zhao, C. (2020). Flaxsed oil alleviates dextran sulphate sodium-induced ulcerative colitis in rats. Journal of Functional Foods, 64, 103602. [CrossRef]
93. 93. Zugaro, S., Benedetti, E., Caioni, G. (2023). Garlic (Allium sativum L.) as an ally in the treatment of inflammatory bowel diseases. Current Issues in Molecular Biology, 45(1), 685-698. [CrossRef]
94. 94. Recinella, L., Gorica, E., Chiavaroli, A., Fraschetti, C., Filippi, A., Cesa, S., Cairone, F., Martelli, A., Calderone, V., Veschi, S., Lanuti, P., Cama, A., Orlando, G., Ferrante, C., Menghini, L., Di Simone, S.C., Acquaviva, A., Libero, M.L., Nilofar, Brunetti, L. (2022). Anti-inflammatory and antioxidant effects induced by Allium sativum L. extracts on an ex vivo experimental model of ulcerative colitis. Foods, 11(22), 3559. [CrossRef]
95. 95. Boakye, Y.D., Mensah, D.O., Agyei, E.K., Agyen, R., Adjei, D.K., Agyare, C. (2022). Health benefits of Garlic (Allium sativum) in gastrointestinal disorders. Goyal, M.R., Birwal, P., Chauhan, N. (Eds.), Herbs, spices and medicinal plants for human gastrointestinal disorders, 1st Edition, Apple Academic Press, (pp. 5-15). New York.